Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Conditions: Resectable MMR-deficient Solid Tumors; Resectable MMR-proficient Solid Tumors Interventions: Drug: botensilimab; Drug: balstilimab Sponsors: The Netherlands Cancer Institute; Agenus Inc. Recruiting

https://clinicaltrials.gov/study/NCT06279130

Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials